

**PAT1(APPBP2) Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7274b****Specification**

---

**PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Product Information**

Primary Accession [O92624](#)  
Other Accession [NP\\_006371](#)

**PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Additional Information**

**Gene ID** 10513

**Other Names**

Amyloid protein-binding protein 2, Amyloid beta precursor protein-binding protein 2, APP-BP2, Protein interacting with APP tail 1, APPBP2, KIAA0228, PAT1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7274b](/products/AP7274b) was selected from the APPBP2 region of human PAT1(APPBP2). A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Protein Information**

**Name** APPBP2 {ECO:0000303|PubMed:26138980, ECO:0000312|HGNC:HGNC:622}

**Function**

Substrate-recognition component of a Cul2-RING (CRL2) E3 ubiquitin-protein ligase complex of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:[29779948](http://www.uniprot.org/citations/29779948), PubMed:[29775578](http://www.uniprot.org/citations/29775578)). The C-degron recognized by the DesCEND pathway is usually a motif of less than ten residues and can be present in full-length proteins, truncated proteins or proteolytically cleaved forms (PubMed:[29779948](http://www.uniprot.org/citations/29779948), PubMed:[29775578](http://www.uniprot.org/citations/29775578)). The CRL2(APPBP2) complex specifically recognizes proteins with a -Arg-Xaa-Xaa-Gly degron at the

C-terminus, leading to their ubiquitination and degradation (PubMed:<a href="http://www.uniprot.org/citations/29779948" target="\_blank">29779948</a>, PubMed:<a href="http://www.uniprot.org/citations/29775578" target="\_blank">29775578</a>). The CRL2(APPBP2) complex mediates ubiquitination and degradation of truncated SELENOP selenoproteins produced by failed UGA/Sec decoding, which end with a -Arg-Xaa-Xaa-Gly degron (PubMed:<a href="http://www.uniprot.org/citations/26138980" target="\_blank">26138980</a>). May play a role in intracellular protein transport: may be involved in the translocation of APP along microtubules toward the cell surface (PubMed:<a href="http://www.uniprot.org/citations/9843960" target="\_blank">9843960</a>).

#### **Cellular Location**

Nucleus. Cytoplasm, cytoskeleton. Membrane; Peripheral membrane protein. Note=Associated with membranes and microtubules.

#### **PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Images**

#### **PAT1(APPBP2) Antibody (C-term) Blocking Peptide - Background**

APPBP2 interacts with microtubules and is functionally associated with beta-amyloid precursor protein transport and/or processing. The beta-amyloid precursor protein is a cell surface protein with signal-transducing properties, and it is thought to play a role in the pathogenesis of Alzheimer's disease. This protein has been found to be highly expressed in breast cancer.

#### **PAT1(APPBP2) Antibody (C-term) Blocking Peptide - References**

Zheng,P., Proc. Natl. Acad. Sci. U.S.A. 95 (25), 14745-14750 (1998)